Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
Trial ID or NCT#
NCT01683084
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.
Official Title
Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms
Eligibility Criteria
Ages Eligible for Study: 50 Years to 85 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
- * 50-85 years of age and able to provide written informed consent* AAA measuring a maximum diameter of 3.5-4.9 cm on CTA or ultrasound* Stable medication regime for the last six months* No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year* High likelihood of compliance with treatment over 24 months
Exclusion Criteria:
- * Renal impairment (i.e. creatinine \>1.5x upper limit of normal \[ULN\])* Known significant renal stenosis (\>70%) of one or both renal arteries* Chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN)* Electrolyte imbalance* Active gout* Current or planned usage of an AT1 blocker or ACE inhibitor* Previous abdominal aortic surgery* Currently pregnant or intend to become pregnant
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Ronald Dalman
6507232169
View on